Updates

Get Alerts
May 22, 2024 | Hurst's the Heart Updates
A Double-Blind, Randomized Placebo-Procedure-Controlled Trial of an Interatrial Shunt in Patients with HFrEF and HFpEF - RELIEVE-HF
Lindsey R. Mitrani, Anu Lala
May 22, 2024 | Hurst's the Heart Updates
PREVENT Trial: Impact of Percutaneous Coronary Intervention in Patients with Vulnerable Non-Obstructive Coronary Plaques
Kyle F. Nelson, Gina LaRocca
May 22, 2024 | Hurst's the Heart Updates
Phase 2 KARDIA-2 Trial
Stephanie Jou, Jeffrey I. Mechanick
May 22, 2024 | Hurst's the Heart Updates
ORBITA-COSMIC: Coronary Sinus Reducer for the Treatment of Refractory Angina
Sean R. Mendez, Gregory Serrao
May 22, 2024 | Hurst's the Heart Updates
IMPROVE-HCM Trial: A Safe Novel Agent for Nonobstructive Hypertrophic Cardiomyopathy
Ashton C. Lai, Martin E. Goldman
May 22, 2024 | Hurst's the Heart Updates
EMPACT-MI Trial Review
Krishan Sharma, Tara Naib
May 22, 2024 | Hurst's the Heart Updates
DanGer Shock
Jason Feinman, Matthew Tomey
May 22, 2024 | Hurst's the Heart Updates
AEGIS-II Trial: Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction
Chris Song, Daniella Kadian-Dodov
December 20, 2023 | Hurst's the Heart Updates
SELECT Trial: Semaglutide in the High-Risk Non-Diabetic Obese Population
Ashton C. Lai, Jeffrey I. Mechanick
December 20, 2023 | Hurst's the Heart Updates
ORBITA-2
Jason Feinman, Matthew Tomey
December 20, 2023 | Hurst's the Heart Updates
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial
Chris Song, Greg Serrao
December 20, 2023 | Hurst's the Heart Updates
Sustained Blood Pressure Reduction With the RNA Interference Therapeutic Zilebesiran: Primary Results From KARDIA-1, a Phase 2 Study in Patients With Hypertension
Sean R. Mendez, Javier Sanz
December 20, 2023 | Hurst's the Heart Updates
Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol - Interim Results of the Phase 1b Heart-1 Trial
Stephanie Jou, Tara Naib
December 20, 2023 | Hurst's the Heart Updates
A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation - AZALEA-TIMI 71
Lindsey R. Mitrani, Jacob Koruth
December 20, 2023 | Hurst's the Heart Updates
ARTESIA: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation
Lindsey R. Mitrani, Daniella Kadian-Dodov
October 27, 2023 | Hurst's the Heart Updates
Semaglutide in Patients with Heart failure with Preserved Ejection Fraction and Obesity: a New Addition to the Armamentarium of Heart Failure Therapies
Christopher Song, Jeffrey Mechanick
October 27, 2023 | Hurst's the Heart Updates
Qiliqiangxin in heart failUre: assESsment of reduction in mortality (QUEST) Study
Lindsey R. Mitrani, Daniella Kadian-Dodov
October 27, 2023 | Hurst's the Heart Updates
OCT versus IVUS versus angiography guidance: a real-time updated network meta-analysis
Sean R. Mendez, Tara Naib
October 27, 2023 | Hurst's the Heart Updates
MULTISTARS AMI: MULTIvessel Immediate versus STAged RevaScularization in Acute Myocardial Infarction
Stephanie Jou, Matthew Tomey
October 27, 2023 | Hurst's the Heart Updates
ECLS-SHOCK Trial Review
Krishan Sharma, Gregory Serrao
October 27, 2023 | Hurst's the Heart Updates
Assessing the Utility of Colchicine to Prevent Atrial Fibrillation After Thoracic Surgery
Adam Russak, Gina LaRocca
October 27, 2023 | Hurst's the Heart Updates
CASTLE-HTx Trial: Atrial Fibrillation Ablation in End-Stage Heart Failure
Ashton C. Lai, Jacob S. Koruth
October 27, 2023 | Hurst's the Heart Updates
ATTRibute-CM
Jason Feinman, Martin Goldman
October 27, 2023 | Hurst's the Heart Updates
ADVENT trial: Pulsed field ablation for paroxysmal atrial fibrillation
Kyle F. Nelson, Javier Sanz
May 12, 2023 | Hurst's the Heart Updates
TRILUMINATE Pivotal Trial
Anton Camaj, Tara Naib